Modern pens and continuous glucose monitors (CGMs) have made this easier, but it is still a commitment
GLP-1 receptor agonists are available in both daily and weekly formulations, each offering distinct advantages depending on patient preference, lifestyle, and clinical circumstances
Hope youll subscribe to this newsletter, and please hit the like button
These factors are creating a strong foundation for mainstream adoption This shift toward multi-indication GLP-1 therapies is redefining treatment protocols and broadening healthcare strategies aimed at chronic disease management
Recent Findings Recent small observational studies and case reports have documented improvements in quality of life, flare frequency, and disease severity among HS patients treated with GLP-1RAs such as liraglutide, semaglutide, dulaglutide, exenatide, and tirzepatide
One in eight people in the world are living with the condition, which has more than doubled in adults since 1990 and quadrupled in adolescents, according to World Health Organization